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ABSTRACT
Introduction: Previous studies have demonstrated 
that hypertensive patients need concomitant 
therapy with one or more drugs from different 
classes of antihypertensive agents to achieve 
their blood pressure control targets. We 
performed the first multinational observational 
study of valsartan/hydrochlorothiazide (HCTZ) 
single pill combination in Asia to determine the 
efficacy, safety, and tolerability in hypertensive 
patients. The objective of this multinational, 
multicenter, 24-week follow-up observational 
study is to evaluate the efficacy, safety, and 
tolerability of valsartan/hydrochlorothiazide 
single pill combination in the treatment of 
essential hypertension in the Asia-Pacific 
region. Methods: A total of 7567 Asian patients 
who were diagnosed with stage 1 or stage 2 
essential hypertension and who took at least 
one dose of valsartan/hydrochlorothiazide 
single pill combination were included in the 
statistical analyses. A total of 59% were taking 
antihypertensive medication at the time of 
the study. Eligible patients received valsartan/
hydrochlorothiazide single pill combination 
80/12.5 mg tablets orally once daily at visit 1. 
The investigator could decide the subsequent 
dose of valsartan/hydrochlorothiazide single 
pill combination for their patients, and efficacy, 
safety, and tolerability data were collected 
at week 4, 12, and 24. Results: Basal blood 
pressure was 155.9±13.3 mmHg (systolic) and 
96.3±10.1 mmHg (diastolic). Response rates 
and control rates increased continuously from 
baseline to the study endpoint at week 24, when 
they reached 94.6% and 73.2%, respectively. 
Systolic and diastolic blood pressure reductions 
were –25.4±15.2 mmHg and –14.9±13.5 mmHg, 
respectively (P<0.001). Using a four-point 
global assessment scale, 96.8% of the patients 
and physicians reported good, very good, or 
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excellent for both their subjective efficacy and 
tolerability assessments. Conclusion: In this 
multicenter, multicountry study including 7567 
Asian patients with hypertension, valsartan/
hydrochlorothiazide single pill combination was 
found efficacious, well tolerated, and devoid of 
any serious adverse effects.
Keywords: Asian; combination therapy; 
efficacy; hypertension; tolerability; valsartan/
hydrochlorothiazide single pill
INTRODUCTION
Hypertension is the most common cardiovascular 
condition in the world and is the leading 
preventable cause of morbidity and mortality 
due to coronary heart disease, stroke, heart 
failure, and kidney failure.1 In the urban adult 
populations of Asia, the prevalence, using the 
criterion of blood pressure (BP) ≥140/90 mmHg, 
varies between 15% and 35%, although it is 
lower in rural areas.2-4 Despite the availability 
of a wide range of antihypertensive drugs, 
mild to moderate hypertension still remains 
poorly controlled.5 Inadequate lowering of 
BP with antihypertensive therapy can be 
attributed to several factors, such as multiple 
pathophysiological mechanisms involved and 
the heterogeneity among patients, the failure of 
physicians to titrate or modify first-line therapy 
to reach the recommended target BP, and the 
lack of patient compliance.6
Despite the efficacy of monotherapy 
with a number of antihypertensive agents, 
approximately 70% of hypertensive patients 
require one or more antihypertensive drugs with 
different mechanisms of action in order to reach 
treatment targets.7 Therefore, the Joint National 
Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC) and 
the World Health Organization (WHO) have 
recently recommended combination therapy as 
a first-line approach for stage 2 hypertension.8 
Combination therapy also has the advantage of 
achieving improved antihypertensive efficacy at 
low individual drug doses compared with those 
used in monotherapy and, therefore, has a lower 
incidence of adverse effects.8
Valsartan, an angiotensin II receptor blocker 
(ARB), lowers BP mainly by blocking the effects 
of angiotensin II on vascular smooth muscle.9 It 
also blocks the aldosterone-mediated retention 
of sodium and excretion of potassium in 
the distal tubule by preventing angiotensin-
initiated aldosterone release from the adrenal 
gland.
Hydrochlorothiazide (HCTZ), a thiazide 
diuretic, is thought to lower BP primarily by 
decreasing sodium resorption in the renal distal 
convoluted tubules.10,11 This sodium depletion 
causes a reflex increase in plasma renin activity, 
a subsequent increase in angiotensin, and in 
aldosterone secretion, and urinary retention of 
sodium accompanied by excretion of potassium. 
Therefore, coadministration of an angiotensin 
II receptor antagonist like valsartan can lessen 
the potassium loss associated with the use of 
thiazide diuretics.12
Increasing amounts of evidence have 
confirmed that combination therapy is the 
preferred treatment regimen to achieve 
satisfactory control of BP in the majority of 
hypertensive patients.7,8 The combination of 
an ARB and low-dose HCTZ does not produce 
any major side effects and provides an 
antihypertensive action significantly greater 
than that of either drug given alone.12-16 The 
objective of this multinational observational 
study is to further evaluate the efficacy, safety, 
and tolerability of valsartan/HCTZ single pill 
combination (SPC) in the treatment of essential 
hypertension in a general clinical practice 
setting. The study design was selected with the 
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aim to collect data from real-world practice 
with a substantial cohort of Asian patients 
representative of the population being prescribed 
valsartan/HCTZ SPC in the Asia-Pacific region. 
MATERIALS AND METHODS
Study Objectives
This multinational, open-label, observational, 
noncomparative, clinical decision-based 
titration study was conducted at 371 centers in 
Asia, including Bangladesh, India, Indonesia, 
Korea (South), Malaysia, Pakistan, Taiwan, and 
Thailand. A total of 8557 patients were enrolled 
in the study. Of these patients, 7567 took at 
least one dose of valsartan/HCTZ SPC and were 
included in the statistical analysis, with 6852 
completing the study (Figure 1). Inclusion 
criteria were (1) male or female subjects ≥18 and 
≤65 years of age; (2) naïve patients with stage 1 
(systolic blood pressure [SBP] 140-159 mmHg/
diastolic blood pressure [DBP] 90-99 mmHg) 
or stage 2 (SBP ≥160 mmHg/DBP ≥100 mmHg) 
essential hypertension, or patients uncontrolled 
on current monotherapy or other combination 
therapy. Exclusion criteria were (1) women who 
were pregnant, intending to become pregnant 
or who were breastfeeding; (2) subjects with 
severe medical conditions that in view of the 
investigator prohibited participation in the 
study (eg, severe renal or hepatic impairment); 
and (3) hypersensitivity to valsartan/HCTZ SPC 
or any of the components in the formulation. 
Figure 1. Study flow chart. ITT=intent to treat; PP=per protocol.
514 subjects
were not enrolled into the trial for not meeting
inclusion/exclusion criteria
8043 subjects
matched the inclusion and
exclusion criteria
Non-ITT population:
476 subjects were not treated
with valsartan + HCTZ
ITT population:
7567 subjects were treated





8557 subjects were screened
715 subjects had no examinations at visit 2, and
were excluded from the PP population:
 Lost to follow-up: 440 (61.5%)
 Withdrew volunarily: 139 (19.4%)
 No longer require valsartan + HCTZ: 66 (9.2%)
 Adverse events(s): 56 (7.8%)
  Dizziness: 11 (19.6%)
  Headache: 4 (7.1%)
  Cough: 3 (5.4%)
 Lack of ecacy: 14 (2.0%)
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Baseline Antihypertensive Medications
Of the 13,936 records for baseline medications, 
3450 were for antihypertensive therapy and 
10,119 for nonantihypertensive therapy, and the 
medications named in the remaining 367(2.6%) 
records could not be reliably identified. 
A total of 2106 (27.8%) were taking 
antihypertensive medication at the start of the 
study. About one-half (1193 patients, 56.6%) 
were on one, 609 patients (28.9%) on two, 221 
patients (10.5%) on three, 56 patients (2.7%) 
on four, and 27 patients (1.3%) on more than 
four antihypertensive medications at baseline. 
Of these patients, 2,053 (97.5%) were taking 
antihypertensive medications that were not 
diuretics, and 210 (10.0%) of them were taking 
diuretics.
Of the 2053 patients who were taking 
antihypertensive medications that were not 
diuretics, 1409/2053 (68.6%) were taking a 
calcium channel blocker, 1114/2053 (54.2%) 
were taking beta blockers, 222/2053 (10.8%) 
were taking alpha blockers, 148/2053 (7.2%) 
were taking an angiotensin-converting enzyme 
inhibitor (ACEI), 72/2053 (3.5%) were taking 
an ARB, 11/2053 (<1%) were taking alpha 2 
agonists, and 10/2053 (<1%) were taking direct 
vasodilators.
Of the 210 patients who were taking diuretics, 
68/210 (32.4%) were taking high-ceiling 
diuretics, 44/210 (21.1%) were taking potassium-
sparing diuretics, 34/210 (16.2%) were taking 
loop diuretics, 37/210 (17.6%) were taking 
thiazide-type diuretics, and 21/210 (10.0%) were 
taking low-ceiling diuretics. 
Diagnosis of hypertension was based on JNC 
7 guidelines17 stage 1 (SBP 140-159 mmHg/DBP 
90-99 mmHg and stage 2 (SBP ≥160 mmHg/DBP 
≥100 mmHg). As this was a noninterventional 
study, previous antihypertensive therapy could 
be continued according to the discretion of 
the clinician. If the previous antihypertensive 
treatment duplicated the study drug treatment, 
the patients were switched from the original 
treatment in order to be enrolled in this study. 
The measurement of BP was performed according 
to usual clinical practice (Korotkoff sound for 
one-time sitting BP measurement or average 
BP of three-sitting BP measurement). The total 
duration of treatment with valsartan/HCTZ 
SPC was 24 weeks. All patients signed informed 
consent forms at the first visit. 
The primary objective of the study was to 
evaluate the efficacy of valsartan/HCTZ SPC 
80/12.5 mg, 160/12.5 mg, and 160/25 mg based 
on the percentage of responders. Responders 
were defined as those with SBP <140 mmHg and/
or DBP <90 mmHg or a reduction of >10 mmHg 
in DBP and/or >20 mmHg in SBP compared 
to baseline values at week 24. The secondary 
objectives of the study were to evaluate the 
reduction in SBP and DBP, to assess the BP 
control rate (percentage of patients whose BP had 
reached the control values of SBP <140 mmHg 
and DBP <90 mmHg), to obtain subjective 
assessments by patients and physicians of the 
efficacy and tolerability of valsartan/HCTZ SPC 
at week 24, and to monitor safety throughout 
the study period.
Treatment
At visit 1 (week 0), eligible patients received a 
prescription for valsartan/HCTZ SPC 80/12.5 mg 
tablets orally once daily. At visit 2 (week 4), the 
investigator decided on the subsequent dose of 
valsartan/HCTZ SPC to be taken, based on the BP 
control achieved by the initial dose. If the BP was 
not controlled (defined as DBP ≥90 mmHg and/
or SBP ≥140 mmHg), the dose of valsartan/HCTZ 
SPC was increased to 160/12.5 mg or 160/25 mg 
once daily, and this dose was continued until 
either the next visit or the end of the study; (2) if 
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the BP was controlled (DBP <90 mmHg and/or 
SBP <140 mmHg), the dose of valsartan/HCTZ 
SPC could also be modified to 160/12.5 mg 
or 160/25 mg if, in the investigator’s clinical 
judgment, a further reduction in BP would be 
beneficial for the patient.
At all subsequent visits, visits 2 (week 4), 
visit 3 (week 12) and visit 4 (week 24), the 
investigator could modify the dose of valsartan/
HCTZ SPC, based on the BP control achieved 
and the tolerability of the dosage used. If at any 
visit the patient’s BP was not controlled with 
the maximum dose of valsartan/HCTZ SPC, the 
investigator had the option of adding another 
suitable antihypertensive, based on clinical 
judgment and experience. All concomitant 
therapy was allowed at the discretion of the 
investigators.
Outcome Measurement
Clinical outcome was measured in terms of the 
reduction in SBP and DBP. Mean±SD reductions 
in SBP and DBP were calculated from baseline 
(week 0) to the end of treatment (week 24). The 
BP control rate was defined as percentage of 
patients achieving the designated control BP (SBP 
<140 mmHg and DBP <90 mmHg). This rate was 
calculated using the frequency distribution at the 
end of treatment (week 24). Global assessment of 
efficacy and tolerability were both evaluated by 
physicians and patients using a four-point scale 
(excellent, very good, good, and poor). Frequency 
distribution was used to perform the analysis 
of these parameters at week 24. An adverse 
event was defined as any untoward medical 
occurrence or clinical investigation in a patient 
administered a pharmaceutical product and did 
not necessarily have a causal relationship to the 
treatment. Worsening of signs and symptoms 
present at the initial visit and the appearance 
of new signs and symptoms after valsartan/
HCTZ SPC administration were considered as 
adverse events. We did not examine potassium 
or creatinine levels or investigate coughs 
specifically, nor did we determine the percentage 
of diabetic patients in this cohort.
Statistical Analysis
Categorical variables were presented as 
counts and percentages, and the chi-square 
test was used to test the associations between 
categorical variables; continuous variables were 
presented as mean±SD. SBP and SBP reductions 
between females and males were compared 
by independent two-sample t test. Repeated 
analysis of covariance was performed to detect 
differences in BP between the initial and the 
four treatment time points. A paired t test was 
performed to detect the difference in BP between 
two time points. Cohen’s kappa was performed 
to demonstrate agreement of the global 
assessments for efficacy and tolerability between 
the patient and their physician (Cohen’s kappa: 
0-0.2, slight agreement; 0.2-0.4, fair agreement; 
0.4-0.6, moderate agreement; 0.6-0.8, substantial 
agreement; 0.8-1.0, almost perfect agreement) 
with a significance level set at 0.05. Statistical 
analyses were performed using SPSS 15.0 software 
(SPSS Inc, Chicago, IL, USA).
RESULTS
Baseline Characteristics
All 7567 patients who took at least one dose 
of valsartan/HCTZ SPC were included in the 
statistical analysis. Patient demographics and 
baseline characteristics are shown in Table 1. In 
all, 55% of patients had stage 2 and 45% stage 
1 hypertension. The mean BP values at baseline 
were 155.9±13.3 mmHg (SBP) and 96.3±10.1 
mmHg (DBP). All patients were Asian, with the 
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following country distribution: Korea (45.2%), 
Taiwan (32.9%), Pakistan (9.8%), Bangladesh 
(5.2%), India (3.2%), Indonesia (3.1%), and 
Malaysia (0.6%).
Efficacy and Tolerability of Valsartan/HCTZ 
SPC
The dose of valsartan/HCTZ SPC in the 0-4 week 
period was 80/12.5 mg for all patients. In the 4-12 
week period, 82.3% of patients were continued on 
this dosage, 14.4% were titrated to a 160/12.5 mg 
dosage, and 2.6% to a 160/25 mg dosage. In the 
12-24 week period, the percentage of patients 
taking the low, initial dosage form remained 
unchanged (82.3%), the percentage taking the 
medium dosage form increased slightly (to 16%) 
and the percentage taking the highest dosage 
decreased slightly (from 2.6% to 1.8%). SBP and 
DBP decreased continuously and significantly 
throughout the study period (Figure 2) (all P 
values <0.05), and were 155.9±13.3 mmHg and 
96.3±10.1 mmHg, respectively (at baseline, 
140.7±13.3 mmHg and 87.2±9.5 mmHg at week 4, 
134.7±12.1 mmHg and 83.8±13.1 mmHg at week 
12, and 130.5±11.4 mmHg and 81.5±11.8 mmHg 
at week 24). 
Response rates, BP control rates, and BP 
reductions are summarized in Table 2. Response 
rate and control rate increased continuously 
from baseline to the end of the study, week 
24, when they reached 94.6% and 73.2%, 
respectively. Mean SBP and DBP reductions 
were –25.4±15.2 mmHg and –14.9±13.5 mmHg, 
respectively at the end of the study (week 24, 
P<0.001). Significant reductions compared to 
baseline values in both SBP and DBP were also 
seen at weeks 4 and 12 (P<0.001).
The global subjective efficacy assessment 
for valsartan/HCTZ SPC is summarized in Table 
3.1. Almost all patients and physicians (96.8%) 
reported good, very good, or excellent for efficacy, 
and 80.6% of the patients reported the same 
global efficacy assessment as their physicians. 
Table 1. Patient demographics and baseline characteristics.
Characteristic Total (n=7567)
Sex, n (%): 
 Female 3147 (41.6)
 Male 4420 (58.4)
Age, years (mean±SD) 52.8±8.3
Height, cm (mean±SD) 163.0±12.4
Weight, kg (mean±SD) 69.4±12.6
SBP, mmHg (mean±SD) 155.9±13.3
DBP, mmHg (mean±SD) 96.3±10.1
HR, beats per minute (mean±SD) 76.2±11.8
Country, n (%): 
 Korea 3420 (45.2)
 Taiwan 2493 (32.9)
 Pakistan 741 (9.8)
 Bangladesh 392 (5.2)
 India 240 (3.2)
 Indonesia 235 (3.1)
 Malaysia 46 (0.6)
DBP=diastolic blood pressure; HR=heart rate; 
SBP=systolic blood pressure.
Figure 2. Serial changes in systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) (mean±SD) from 
baseline to week 24. *Indicates a significant difference in 
blood pressure compared to baseline (P values <0.05). 
†Indicates a significant difference in blood pressure 
compared to week 4 visit (P values <0.05). ‡Indicates a 
significant difference in blood pressure compared to week 
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A significant Cohen’s kappa of 0.755 (P<0.001) 
showed moderate agreement for efficacy 
assessments between patients and physicians.
The global assessment for tolerability of 
valsartan/HCTZ SPC is summarized in Table 3.2. 
Again, almost all patients and physicians 
(96.8%) reported good, very good, or excellent 
for the tolerability assessment, and 81.1% of the 
patients reported the same global assessments 
as their physicians. A significant Cohen’s kappa 
of 0.768 (P<0.001) showed moderate agreement 
for tolerability assessments between patients and 
physicians.
Association Between Treatment Response 
and Age
A significant association between age and 
response was found at week 4; the response rates 
were 65.6% for those younger than 50 years and 
Table 2. Efficacy endpoints at weeks 4, 12, and 24.
Endpoint Week 4 (n=7298) Week 12 (n=6832) Week 24 (n=6573)
DBP reduction >10 mmHg, n (%) 2162 (29.6) 3541 (51.8) 4254 (64.7)
SBP reduction >20 mmHg, n (%) 1686 (23.1) 2899 (42.4) 3774 (57.4)
SBP reduction >20 mmHg or DBP reduction  2804 (38.4) 4413 (64.6) 5105 (77.7) 
>10 mmHg, n (%)
DBP <90 mmHg, n (%) 3830 (52.5) 5064 (74.1) 5527 (84.1)
SBP <140 mmHg, n (%) 2747 (37.6) 4335 (63.5) 5243 (79.8)
SBP <140 mmHg or DBP <90 mmHg, n (%)  4366 (59.8) 5553 (81.3) 5956 (90.6)
Responder, n (%)* 4919 (67.4) 6022 (88.1) 6216 (94.6)
Blood pressure controlled, n (%)† 2211 (30.3) 3846 (56.3) 4814 (73.2)
Reduction of blood pressure, mean±SD:   
 Systolic –15.27±14.10 –21.17±14.90 –25.38±15.23
 Diastolic –9.12±9.79 –12.54±14.17 –14.85±13.51
Missing values among the intent-to-treat (ITT) population were 269 (3.6%), 735 (9.7%), and 994 (13.1%) at week 4, week 
12, and week 24, due to no blood pressure examinations.
*Responders were defined as those patients with SBP <140 mmHg and/or DBP <90 mmHg, or a reduction of >10 mmHg in 
DBP and/or a reduction of >20 mmHg in SBP compared to baseline.
†Blood pressure controlled was defined as SBP <140 mmHg and DBP <90 mmHg.
DBP=diastolic blood pressure; SBP=systolic blood pressure.
Table 3.1. Agreement of global assessment for efficacy by patients and physicians (n=6705).
   By patients (n=6705) 
Assessment for efficacy  Poor Good Very good Excellent Total
By physicians, n (%) Poor 110 (1.6) 11 (0.2) 1 (0.0) 0 (0.0) 122 (1.8)
 Good 73 (1.1) 1196 (17.8) 225 (3.4) 9 (0.1) 1503 (22.4)
 Very good 17 (0.3) 370 (5.5) 2,711 (40.4) 219 (3.3) 3317 (49.5)
 Excellent 5 (0.1) 24 (0.4) 345 (5.1) 1389 (20.7) 1763 (26.3)
Total, n (%)  205 (3.1) 1601 (23.9) 3282 (48.9) 1617 (24.1) 6705 (100.0)
n=6705, instead of 7567, due to 862 (11.4%) subjects in the intent-to-treat population who had no assessment for efficacy 
either by themselves or by physicians.
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68.5% for others older than 50 years (P=0.010). 
At week 12 and week 24, no significant 
association with age was found for response rate 
and BP control rate. For those patients younger 
than 50 years, DBP was reduced about 1 mmHg 
more than in patients older than 50 years of age 
at all times measured (P<0.001) (Supplementary 
Table 1).
Association Between Treatment Response 
and Gender
At week 4, the response rate and control rate 
in females was significantly higher than in 
males (response rate: 69.6% vs. 65.8%, P=0.001; 
control rate: 32.9% vs. 28.4%, P<0.001), and 
SBP reduction in females was significantly 
greater than that in males (–15.96±14.73 vs. 
–14.79±13.62 mmHg, P=0.001). At weeks 12 and 
24, DBP reduction in females was significantly 
less than that in males (–11.89±18.25 vs. 
–12.99±10.37 mmHg at week 12, P=0.002; 
–14.45±10.21 vs. –15.13±15.40 mmHg at week 
24, P=0.046) (Table 4).
Safety of Valsartan/HCTZ SPC
The safety of valsartan/HCTZ SPC was assessed 
by the number of adverse events that occurred 
during the study period. A total of 1747 
adverse events were recorded for patients who 
took valsartan/HCTZ SPC at least once, and of 
these events, 1582 (90.6%) were thought to be 
unrelated to the study drug. Among the 7567 
patients, 1082 patients (14.3%) experienced at 
least one adverse event, 262 patients (3.46%) 
reported two adverse events, and 152 patients 
(2.01%) reported more than two adverse events. 
Four (0.23%) serious adverse events were 
reported, including coronary artery disease, 
hypoglycemia, non-ST elevation myocardial 
infarction, and upper gastrointestinal bleeding. 
None of these serious adverse events were 
suspected to be due to valsartan/HCTZ SPC 
administration.
DISCUSSION
In this multinational observational study, 
significant SBP and DBP reduction was found 
at all time points during the study, with early 
achievement of the BP goal (140.7/87.2 mmHg, 
at week 4) and additional significant reduction 
at weeks 12 and 24. By the end of the study 
(week 24), almost all (94.6%) patients were 
responsive to valsartan/HCTZ SPC, and 73.2% 
of these responsive patients achieved the desired 
degree of BP control. Based on the proportion 
of patients achieving the desired SBP and DBP 
values, valsartan/HCTZ SPC exhibited a high 
Table 3.2. Agreement of global assessment for tolerability by patients and physicians (n=6671).
  By patients (n=6671) 
Assessment for tolerability Poor Good Very good Excellent Total
By physicians, n (%) Poor 112 (1.7) 14 (0.2) 2 (0.0) 0 (0.0) 128 (1.9)
 Good 68 (1.0) 1245 (18.7) 223 (3.3) 10 (0.1) 1546 (23.2)
 Very good 14 (0.2) 341 (5.1) 2,647 (39.7) 184 (2.8) 3186 (47.8)
 Excellent 4 (0.1) 35 (0.5) 341 (5.1) 1431 (21.5) 1811 (27.1)
Total, n (%)  198 (3.0) 1635 (24.5) 3213 (48.2) 1625 (24.4) 6671 (100.0)
n=6671 instead of 7567 because 896 (11.8%) subjects in the intent-to-treat population had no assessment for tolerability 
either by themselves or by physicians.
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degree of efficacy in this population (that is, in 
Asian adults, male and female naïve patients 
with stage 1 or stage 2 hypertension, or who were 
poorly controlled on their respective ongoing 
monotherapy or combination therapy).
Results of population studies vary by countries, 
as well as different prescription behaviors. Low 
prescription rates for combination therapy, 
42.2% and 35.3%, were reported in studies 
from India and Japan, respectively, and ARB/
HCTZ was not the most popular combination 
selected.18,19 In contrast, more than half (64%) 
of US hypertensive patients were prescribed 
combination therapy, with the majority of 
these prescriptions (27%) as ARB or ACEI in 
combination with diuretics.20
A previous descriptive cross-sectional study 
reported that only 59% of hypertensive patients 
were under adequate control with treatment.21 
A meta-analysis of several randomized, 
double-blind studies comparing valsartan 
monotreatment with combination treatment22 
concluded that combination therapy was more 
effective in terms of response rate. 
In the current study, we noticed that the 
younger patients (<50 years old) showed more 
DBP reduction than older patients. However, a 
current study by Asmar and Oparil showed older 
patients (>65 years old) achieve a greater DBP 
reduction than younger patients.23 Although the 
difference was only 1 mmHg, it was statistically 
significant. The correlation between age and BP 
reduction will require additional confirmation 
in future investigations, and the clinical 
interpretation should be further discussed.
Regardless, in the current study, females 
showed a significantly smaller DBP reduction 
than males at week 12 and week 24. However, 
the difference between males and females was 
only 1 mmHg, and the significance is marginal 
at week 24. In the Asmar and Oparil study, 
females also showed a 1 mmHg smaller DBP 
reduction than males, but this difference was 
not statistically significant.23
Treatment with valsartan/HCTZ SPC was 
well tolerated for most patients, and almost all 
patients rated the tolerability with good or better. 
Almost all patients also rated the combination 
as efficacious, but because mild hypertension is 
symptomless, this subjective judgment reflected 
whether the patient’s BP had reached a value the 
patient thought acceptable, rather than whether 
actual control had been achieved.
Choice of antihypertensive drugs depends on 
cost, anticipated side effects, and the physician’s 
familiarity with the drug. Clinical trials have 
shown valsartan/HCTZ to be more effective than 
either drug alone and to have an adverse effect 
profile similar to that of placebo.19 The current 
study is the largest study to date, and includes 
7567 Asian patients in a general clinical practice 
setting treated with valsartan/HCTZ SPC. The 
results reflect a real life situation as the patients 
included in this study represent the general 
population being prescribed valsartan/HCTZ 
SPC specifically in the Asia-Pacific region. The 
low incidence of adverse effects confirmed the 
safety of treatment in this study cohort. The 
results also confirm that combination therapy 
as first-line approach in stage 2 hypertension as 
recommended by WHO and the JNC8 is efficacious 
and well tolerated in Asian patients. However, 
45% of the patients in the study had stage 1 
hypertension, and because we did not investigate 
thiazide monotherapy, we cannot say whether 
valsartan/HCTZ is more efficacious than thiazide 
monotherapy in stage 1 hypertension. But in 
cases where two drugs need to be prescribed, it 
has been demonstrated that SPC treatment is 
associated with better compliance and a smaller 
pill burden. Antihypertensive therapy is always 
long lasting. Further research is required with 
this drug combination in Asian hypertension 
patients beyond 24 weeks of treatment in order 
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to confirm that the benevolent safety profile 
and efficacy can be maintained in the long run. 
Whether first line combination therapy has an 
effect on the number of therapies required in the 
future in order to obtain BP control will also be 
in the area of interest.
One limitation of the study was that there 
was a lack of data on patients who changed their 
nonstudy antihypertensive drug(s) during the 
course of the study. Another is that there was 
insufficient data necessary to perform subgroup 
analyses.
CONCLUSION
In summary, this multicenter, multicountry 
study consisting of 7567 Asian patients with 
essential hypertension, demonstrated valsartan/
HCTZ SPC to be highly effective, well tolerated, 
and devoid of any serious adverse effects in a 
general practice setting. 
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